Krystal Biotech (NASDAQ:KRYS) Delivers Strong Q2 Earnings and VYJUVEK Revenue Growth

Font: Financial Modeling Prep  • Aug 03, 2026

• Krystal Biotech (NASDAQ:KRYS) exceeded analyst expectations with its Q2 earnings per share (EPS) of $1.79.
• The company reported robust revenue growth, reaching $119.22 million, primarily driven by strong global sales of its VYJUVEK therapy.
• Krystal Biotech maintains a solid financial position with over $1.1 billion in cash and investments and a very low debt-to-equity ratio.

Krystal Biotech (NASDAQ:KRYS) is a leading biotechnology company that specializes in developing innovative treatments for rare diseases. Its flagship commercial product is VYJUVEK, a groundbreaking gene therapy for patients suffering from dystrophic epidermolysis bullosa (DEB). DEB is a severe rare genetic condition characterized by extremely fragile skin and easy blistering.

On August 3, 2026, Krystal Biotech announced its impressive second-quarter results, posting an earnings per share (EPS) of $1.79. This figure significantly beat the analyst consensus estimate of $1.70, as highlighted by Zacks. This also marks a substantial increase from the $1.29 per share reported in the same quarter a year earlier, showcasing strong biotech stock performance.

The company's revenue for the quarter was $119.22 million. While this figure narrowly missed one analyst estimate of $121.13 million, it represents a remarkable 24% increase from $96 million in the prior-year period. This robust revenue growth is primarily driven by the global sales of VYJUVEK, which have now reached a cumulative total of $965.90 million since its initial launch, underscoring the therapy's market success.

The strong VYJUVEK revenue performance is attributed to expanding treatment access for patients. In the U.S., net revenue for VYJUVEK reached $91.60 million. Krystal Biotech has successfully secured more than 730 U.S. reimbursement approvals, which is crucial for patient access to the treatment and ensures the company's financial stability through product payments.

Krystal Biotech maintains a strong financial position, ending the quarter with over $1.1 billion in cash and investments. The company boasts a very low debt-to-equity ratio of 0.0013. This indicates that Krystal Biotech uses very little borrowed money to fund its operations, which is a significant sign of robust financial stability and a positive indicator for biotech investment insights.